Prosultiamine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592945

CAS#: 59-58-5

Description: Prosultiamine is used for treatment of lower urinary tract dysfunction.

Chemical Structure

img
Prosultiamine
CAS# 59-58-5
Instruction

Theoretical Analysis

MedKoo Cat#: 592945
Name: Prosultiamine
CAS#: 59-58-5
Chemical Formula: C15H24N4O2S2
Exact Mass: 356.13
Molecular Weight: 356.500
Elemental Analysis: C, 50.54; H, 6.79; N, 15.72; O, 8.98; S, 17.99

Price and Availability

Size Price Availability Quantity
1g USD 205 2 Weeks
5g USD 385 2 Weeks
25g USD 745 2 Weeks
100g USD 1345 2 Weeks
Bulk inquiry

Synonym: Prosultiamine; NSC 23893; NSC-23893; NSC23893

IUPAC/Chemical Name: Formamide, N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl)-

InChi Key: UDCIYVVYDCXLSX-SDNWHVSQSA-N

InChi Code: InChI=1S/C15H24N4O2S2/c1-4-7-22-23-14(5-6-20)11(2)19(10-21)9-13-8-17-12(3)18-15(13)16/h8,10,20H,4-7,9H2,1-3H3,(H2,16,17,18)/b14-11+

SMILES Code: O=CN(CC1=CN=C(C)N=C1N)/C(C)=C(SSCCC)\CCO

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 356.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. Int J Urol. 2018 Jan;25(1):54-60. doi: 10.1111/iju.13468. Epub 2017 Oct 1. PubMed PMID: 28965354.

2: Ogawa T, Kato T, Ono M, Shimizu T. [Clinical and MRI Findings in Patients with Congenital Anosmia]. Nihon Jibiinkoka Gakkai Kaiho. 2015 Aug;118(8):1016-26. Japanese. PubMed PMID: 26548095.

3: Kira J. Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Med. 2013 Aug 15;11:183. doi: 10.1186/1741-7015-11-183. PubMed PMID: 23945332; PubMed Central PMCID: PMC3826871.

4: Nakamura T, Matsuo T, Fukuda T, Yamato S, Yamaguchi K, Kinoshita I, Matsuzaki T, Nishiura Y, Nagasato K, Narita-Masuda T, Nakamura H, Satoh K, Sasaki H, Sakai H, Kawakami A. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Med. 2013 Aug 15;11:182. doi: 10.1186/1741-7015-11-182. PubMed PMID: 23945290; PubMed Central PMCID: PMC3826868.

5: Oka H, Tsuzuki K, Takebayashi H, Kojima Y, Daimon T, Sakagami M. Olfactory changes after endoscopic sinus surgery in patients with chronic rhinosinusitis. Auris Nasus Larynx. 2013 Oct;40(5):452-7. doi: 10.1016/j.anl.2012.12.001. Epub 2013 Jan 11. PubMed PMID: 23312885.

6: Takakura H, Shojaku H, Takamoto K, Urakawa S, Nishijo H, Watanabe Y. Cortical hemodynamic responses to intravenous thiamine propyldisulphide administration detected by multichannel near infrared spectroscopy (NIRS) system. Brain Topogr. 2011 Jun;24(2):114-26. doi: 10.1007/s10548-011-0179-9. Epub 2011 Mar 29. PubMed PMID: 21445664.

7: Nishiura Y, Nakamura T, Fukushima N, Nakamura H, Ida H, Aramaki T, Eguchi K. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther. 2009;14(4):533-42. PubMed PMID: 19578238.

8: Irifune K. [Effect of Alinamin F and Kakkontou on mucoid Pseudomonas aeruginosa chronic lower respiratory tract infection]. Nihon Kokyuki Gakkai Zasshi. 2009 Mar;47(3):218-21. Japanese. PubMed PMID: 19348269.

9: Miyanari A, Kaneoke Y, Noguchi Y, Honda M, Sadato N, Sagara Y, Kakigi R. Human brain activation in response to olfactory stimulation by intravenous administration of odorants. Neurosci Lett. 2007 Aug 9;423(1):6-11. Epub 2007 Jul 5. PubMed PMID: 17658690.

10: Saito K, Takahashi M, Fukuta K, Tachibana E, Yoshida J. Recovery of olfactory function after an anterior craniofacial approach. Skull Base Surg. 1999;9(3):201-6. PubMed PMID: 17171090; PubMed Central PMCID: PMC1656739.

11: Miyanari A, Kaneoke Y, Ihara A, Watanabe S, Osaki Y, Kubo T, Kato A, Yoshimine T, Sagara Y, Kakigi R. Neuromagnetic changes of brain rhythm evoked by intravenous olfactory stimulation in humans. Brain Topogr. 2006 Spring;18(3):189-99. Epub 2006 Mar 1. PubMed PMID: 16544208.

12: Nakashima T, Kidera K, Miyazaki J, Kuratomi Y, Inokuchi A. Smell intensity monitoring using metal oxide semiconductor odor sensors during intravenous olfaction test. Chem Senses. 2006 Jan;31(1):43-7. Epub 2005 Dec 1. PubMed PMID: 16322087.

13: Hirakawa K. [Prognosis in olfaction disorders]. Nihon Jibiinkoka Gakkai Kaiho. 2004 Oct;107(10):937-42. Review. Japanese. PubMed PMID: 15658010.

14: Hatanaka S, Ishimaru T, Yata T, Miwa T, Furukawa M. Potential oscillation elicited by i.v. olfaction and its applicability as an objective clinical olfaction test. Acta Otolaryngol Suppl. 2004 Aug;(553):65-73. PubMed PMID: 15277040.

15: Ishimaru T, Yata T, Hatanaka-Ikeno S. Hemodynamic response of the frontal cortex elicited by intravenous thiamine propyldisulphide administration. Chem Senses. 2004 Mar;29(3):247-51. PubMed PMID: 15047599.

16: Harada H, Rikimaru F, Mori T, Tanaka M, Shiraishi K, Kato T. Electroencephalographic changes during intravenous olfactory stimulation in humans. Clin Electroencephalogr. 2002 Oct;33(4):189-92. PubMed PMID: 12449851.

17: Ishimaru T, Hatanaka S, Yata T, Horikawa I, Tsukatani T, Nishimura T, Miwa T, Furukawa M. Potential changes with gamma-band oscillation at the frontal scalp elicited by intravenous olfactory stimulation in humans. Chem Senses. 2002 Oct;27(8):711-7. PubMed PMID: 12379595.

18: Yamagishi M, Hasegawa S, Suzuki S, Nakamura H, Nakano Y. Effect of surgical treatment of olfactory disturbance caused by localized ethmoiditis. Clin Otolaryngol Allied Sci. 1989 Oct;14(5):405-9. PubMed PMID: 2582635.

19: Nishioka K, Katayama I, Masuzawa M, Yokozeki H, Nishiyama S. Drug-induced chronic pigmented purpura. J Dermatol. 1989 Jun;16(3):220-2. PubMed PMID: 2507607.

20: Okabe E. [A study on the mechanism of phleboid olfactory function]. Nihon Jibiinkoka Gakkai Kaiho. 1989 Jan;92(1):111-20. Japanese. PubMed PMID: 2723880.